# INV-1120

Source: https://onco.cc/drugs/inv-1120/  
OnCo record `inv-1120` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INV-1120 is an experimental EP4 antagonist from Shenzhen Ionova Life Sciences, in phase 1 trials for advanced solid tumours.

## Summary

INV-1120 is an EP4 antagonist from Shenzhen Ionova Life Sciences. An EP4 inhibitor (antagonist) tested alone and with pembrolizumab in advanced solid tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry status RECRUITING (phase 1) on 3 Nov 2026; the company's latest INV-1120 news is from Nov 2022. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: INV-1120
- Modality: EP4 antagonist
- Mechanism: An EP4 inhibitor (antagonist) tested alone and with pembrolizumab in advanced solid tumours.

## Sources

- Shenzhen Ionova Life Sciences: ionovabio.com: https://www.ionovabio.com/en/companynews
- Shenzhen Ionova Life Sciences: ionovabio.com: https://www.ionovabio.com/companynews
- Shenzhen Ionova Life Sciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT04443088
- ClinicalTrials.gov: trials of INV-1120: https://clinicaltrials.gov/search?intr=INV-1120

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [EP4 (PTGER4)](https://onco.cc/targets/ep4/)
- companies: [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/)
- trials: [An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct04443088/)

---
JSON: https://onco.cc/api/v1/entities/inv-1120.json